Nucleai
Michael Pellini is a seasoned executive with extensive experience in the biotechnology and healthcare sectors. Currently, Michael serves as Managing Partner at Section 32, a position held since December 2017. Prior to this role, Michael was the Chairman and CEO of Foundation Medicine, Inc. from April 2011 to July 2018, and served as President and COO at Clarient, Inc. from June 2007 to April 2011. Michael holds a Bachelor's Degree in Economics from Boston College and an MBA in Finance from Drexel University's LeBow College of Business, along with an additional MBA from the same institution.
This person is not in the org chart
This person is not in any offices
Nucleai
7 followers
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects.